TELA Bio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M | -$29.5M |
| Operating expenses | $88.1M | $88.2M | $84.2M | $66.1M | $48.3M |
| Cash from operations | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M |
| Capital expenditure | $448,000 | $989,000 | $611,000 | $872,000 | $627,000 |
| Free cash flow | -$28.7M | -$42.6M | -$41.5M | -$41.6M | -$31.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M |
Shares outstanding 44.8M · Free float 69.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.